Therefore, we hypothesize that a two-step personalized therapy strategy of targeting both T/E fusion and NF-κB signaling, which is similar to the approach for SPINK1+/ETS− PCas as discussed previously [38], may be a viable approach for this subgroup of PCa who carries T/E fusion. The gene discussed is SPINK1; the disease is posterior cortical atrophy.